Bob Stern Email & Phone Number

Sanibel, Fl, Us

Following open heart surgery, patients often experience rhythm disturbances which can lead to serious complications during recovery. To counter this, cardiac surgical patients are typically fitted with a temporary pacing system in order to regulate the heart’s rhythm and ensure a near-normal cardiac output is maintained.Post-surgical temporary pacing therapy is achieved by attaching a pacing wire to the outer surface of the heart, feeding the wire through the patient’s abdomen, and attaching this to an extension lead which is inserted into a temporary pacing device that is kept at the bedside.Research and experience show epicardial pacing wires to be both unstable and subject to degeneration from epithelialisation (scar tissue formation), with published articles highlighting the potential dangers of temporary pacing and recommending that checks on the pacing parameters of such devices be performed at least every 12 hours.This instability, coupled with devices that lack the sophistication seen in modern permanent pacing, as well as device management typically undertaken by ITU doctors and nurses operating in high pressured environments, can lead to a failure to identify acute and sudden changes in device function or patient underlying rhythm. As a result, cardiac output may be affected, resulting in higher use of inotrope (muscle contraction) medication and an extended and costly ITU stay. Other more serious consequences of a failure to recognize acute changes in pacing function can lead to serious harm to the patient, including causing cardiac arrest and death.

This first-in-category Intrasaccular Device to be used as acute and long-term solution, For both bifurcation and sidewall aneurysms

Eden Prairie, Mn, Us

MIVI is on a mission to deliver groundbreaking solutions for improving outcomes in challenging neurointerventional procedures. We go beyond current options to solve two major unmet needs identified by neurointerventionalists—improving aspiration outcomes for strokes, and reducing distal embolization.

Irvine, Ca, Us

President and Chief Executive OfficerMember of the Board Of Directors

Irvine, Ca, Us

Fully focused on improving acute stroke treatment, Neuravi develops and globally markets innovative medical devices for neurointerventional therapy that are based upon extensive research into the clot and occlusions that cause stroke. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.

Company sold to Covidien/MDT

Flexible Stenting was acquired by JNJ March 2013

Micrus Endovascular Corporation (NASDAQ: MEND) develops and markets products that are used in the minimally invasive treatment of cerebral aneurysms and ischemic stroke. Proprietary Micrus microcoils and access platforms provide a safe and reliable alternative to a highly invasive and costly neurosurgical procedure (craniotomy and aneurysmal clipping) that requires extended operating room and recovery times. Micrus’ microcoils, combined with its access products such as guidewires, balloon catheters, guide cathers and microcatheters, allow physicians to treat cerebral aneurysms less invasively through the arterial system. Micrus markets its products through a direct sales force in North America and parts of Europe, and through distributors in Japan, Europe, Latin America, Asia and the Middle East.

Context Connect, LLC. (“CCL”) is a privately-held company dedicated to revolutionizing the way individuals ‘find and connect’ to one another, privately. Context Connect provides a proprietary technology that 1) allows for simple directory-based connectivity and other transactions between individuals, 2) retains the privacy of individual’s information and 3) generates communication-based transactions for service providers such as social networking sites and carriers.Context Connect is headquartered in Boston, Massachusetts with offices in Wellington, New Zealand. Investors in Context Connect include Equity Resource Investments, Bingham McCutchen (via the Gould Fund), Sitel Corporation and Bay Resource Corporation.The company has developed a robust portfolio of intellectual property throughout the world focused on the area of private, directory-based connectivity.The company offers a simple directory platform that allows individuals to ‘find and connect’ one another without revealing the actual contact information of the target subscriber. Through the company’s Directory as a Service (Daas) Platform, the ‘click to talk’ widgets allow people to get connected based on contextual names or aliases that they control and manage, rather than phone numbers or contact information that are 1) private to individuals and 2) hard to remember

Qixel Capital Group, Inc. is an Internet holding company that cultivates companies focused on the development of business-to-business eCommerce in Asia/Pacific. Qixel's specialized services enhance Internet infrastructure in Southern Hemisphere and Pacific-rim countries by partnering with local companies to build efficiencies, speed learning curves and deploy proven Internet solutions in new markets. Through its existing network of eCommerce-focused companies, Qixel provides a variety of resources to enable end-to-end eCommerce solutions for nascent market entrants.

Led, legal, accounting, and finance team through public offering as InnerDyne, Inc.Developed infrastructure, which led to profitability in 28 months after $52 million in sequential lossesDeveloped IT and WAN systems for manufacturing and financial management Responsible for strategic planning and negotiation of corporate alliances (AHP,SDG. )Responsible for all finance related issues including, banking, corporate finance, P&L, treasury, risk management, forecastingResponsible for IR program and buy and sell side analytical coverage.Responsible as the senior financial officer for all public filings, press releases and investor reportingDeveloped and filed a series of radioisotope and drug delivery patents, focused on restenosis, and oncology these technologies are currently in animal trials

Responsible for Worldwide technology and product licensing.Established a European business and research division.Manage all domestic and international business affairs.Negotiated all marketing, manufacturing and distribution agreements. Successfully negotiated agreements with 5 multi-national companies to commercialize three radiopharmaceutical products.

Bs, Business Administration And Management, Finance

Mba, Business